Wells Fargo Sees Strong Upside in Tandem Diabetes After Fast Pharmacy Progress
Wells Fargo upgraded Tandem Diabetes, raising price target to $27 on strong growth, better pharmacy model, and positive outlook.
/ 1653 items
#XY↓
No More Shots for Kids! FDA Approves Inhaled Afrezza 6+
The FDA has just approved MannKind’s Afrezza—the first inhaled insulin for children aged 6 and older with Type 1 and Type 2 diabetes.
Oculis DIAMOND Trial Results: Vision Goal Not Met, But Retina Improved – Company Shifts Focus
Oculis eye drops failed main vision goal in DME trials but reduced swelling; no FDA filing, company shifts focus, strong cash until 2029.
C4 Therapeutics Shares Rocket as Bristol Myers Squibb’s Mezigdomide Phase 3 Triumph Lights Up Protein Degrader Sector
C4 Therapeutics stock jumped after Bristol Myers Squibb announced strong Phase 3 SUCCESSOR-2 results for mezigdomide in multiple myeloma.
Truist Bullish on ArriVent: $45 Target on Firmonertinib’s Lung Cancer Potential
Truist is bullish on ArriVent, rating Buy and seeing firmonertinib as a strong lung cancer drug with up to $1.1B peak sales.
Sensei Biotherapeutics Gets Wall Street Backing as PIKTOR Advances in Breast & Endometrial Cancer
Cantor is bullish on Sensei Biotherapeutics for its cancer drug PIKTOR, with Phase 2 data soon as a key stock catalyst.